Desirudin

Drug Profile

Desirudin

Alternative Names: CGP 39393; Desulfatohirudin recombinant; Iprivask; r-Hirudin; Revasc

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Canyon Pharmaceuticals
  • Class Anticoagulants; Antithrombotics; Hirudins; Recombinant proteins
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Deep vein thrombosis
  • No development reported Thrombosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Thrombosis(Prevention) in Unknown (IV)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Thrombosis(Prevention) in USA (SC)
  • 23 Feb 2015 Valeant Pharmaceuticals acquires desirudin from Marathon Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top